Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five casesCynthia M. Magro, Jeffrey Laurence, J. Justin Mulvey et al.|Translational research|2020Cited by 2.3k
Anti-complement C5 therapy with eculizumab in three cases of critical COVID-19Jeffrey Laurence, Cynthia M. Magro, J. Justin Mulvey et al.|Clinical Immunology|2020Cited by 128
Severe COVID-19: A multifaceted viral vasculopathy syndromeCynthia M. Magro, Gerard J. Nuovo, Justin Mulvey et al.|Annals of Diagnostic Pathology|2020Cited by 109
The differing pathophysiologies that underlie COVID‐19‐associated perniosis and thrombotic retiform purpura: a case seriesCynthia M. Magro, Gerard J. Nuovo, J. Justin Mulvey et al.|British Journal of Dermatology|2020Cited by 107
Eculizumab in the treatment of refractory idiopathic thrombotic thrombocytopenic purpuraJohn Chapin, Jeffrey Laurence, Babette B. Weksler et al.|British Journal of Haematology|2012Cited by 99